Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension

NCT04936035 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.

NCT NCT04936035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04936035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Efficacy and Safety of ALN-AGT01 in Patients With Mild-to-Moderate Hypertension
Lead sponsor
Alnylam Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
July 7, 2021
Completion date
December 5, 2024
Enrollment
394 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension